The medical breakthrough will significantly reduce cost and increase compliance in patients undergoing antifungal therapy
Intas Pharmaceuticals has made a progressive breakthrough in the antifungal therapy domain with the launch of the world’s first Super Bioavailable Itraconazole-SB 100mg by the Brand Name of Itaspor-SB Forte/Subawin. It has been recently approved by Indian regulatory authorities.
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage, antacids consumption etc. and overall cost of the treatment.
Itaspor SB Forte/Subawin is expected to improve patient compliance and reduce the Doctor’s counselling time. It will reduce dosing to half. Furthermore, patients can take it with or without a meal with just water or as directed by the physician. The cost of the therapy is also reduced substantially.
As per published literature and clinicians’ experience, the Itraconazole molecule has low blood drug concentration, affecting safety and efficacy when taken orally. These blood levels highly vary from patient to patient. Moreover, the recommendation to take it with a full fatty meal and an acidic beverage further reduces patient compliance and adds to the problem of desired blood drug concentration. Another factor is the cost of therapy for fungal infection patients, as treatment duration varies from three to eight weeks.
“Intas’ newest formulation within the 25-year-old brand Itaspor is formulated with Super Bioavailable (SB) Technology that makes 1 Itaspor-SB Forte capsule equivalent to conventional 200mg Itraconazole,” said Dr Alok Chaturvedi, Senior VP and Head – Medical Affairs, Intas Pharmaceuticals.